# Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

> **NCT00869557** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 71 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** Stribild
- **DRUG:** Atripla

## Key facts

- **NCT ID:** NCT00869557
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-11
- **Final completion:** 2013-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869557, "Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00869557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*